Visualization of Eluvia Drug-Eluting Stent, from side close-up.
ELUVIA™ DRUG-ELUTING STENT

Exceptional design.
Exceptional outcome.

Vascular Surgery / Drug-Eluting Therapies / Eluvia DES / Eluvia DES Technology

 

Three confident healthcare professionals in operating room, looking at screen.

NEXT-GENERATION TECHNOLOGY

Innovation meets
efficient drug transfer.

Eluvia DES is designed to meet the challenges of the SFA with outstanding flexibility and precise stent placement. Only Eluvia DES offers sustained drug release, with the world’s most proven polymer, to match the restenotic process of SFA.

Polymer Designed for Controlled Drug Release

Eluvia DES has the lowest drug dose1 (0.167 µg/mm2) delivered by the world’s most proven polymer. Built to ensure targeted delivery to the lesion while minimizing downstream particulates and features the lowest systemic drug exposure for the patient among all peripheral paclitaxel-based technologies2.

 

Infographic of Eluvia drug eluting stent illustrating 92.1% patency at one year.


Downstream Impact

Eluvia’s polymer minimizes downstream particulates and showed similar particulate loss compared to a bare metal stent3.

Illustration of Eluvia DES particulates vs bare metal stent illustration.


Eluvia DES Product Details

Eluvia matrics illustrating stent lengths


Triaxial Delivery System

Built for more precise and predictable stent placement.

Innova self-expanding nitinol stent system for Superficial Femoral Artery (SFA)
1. Drug dose data from Eluvia DES, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use.
2. PK Data from Eluvia DES, Lutonix 018 DCB, Lutonix 035 DCB, Stellarex 035 DCB and Ranger DCB Instructions for Use.
3. Data on file at Boston Scientific. Devices were tested in simulated-use conditions in a tortuous vessel model under clinically relevant flow conditions. Downstream particulates collected with a polycarbonate filter.
image



RESTENOSIS REPLACEMENT PROGRAM

Standing together.

The Bold Step Program is a statement of our confidence in the efficacy of our drug-eluting products. The program offers an Eluvia DES or Ranger DCB at no additional charge if a patient requires reintervention within the first year due to restenosis. 
Medical staff gloved hands holding guidewire during surgery

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Surgeon using triaxial delivery system during surgery

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

take the fight to pad
Top